Randomised controlled trialindependent cross-checkabstract checked★ key study I-GRN-108 in-depth review

Two weeks of gluten damages the gut in coeliac disease even when symptoms fade

Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.

Overview

Leffler D et al.. Gut 2013 · PMID 22619366 · DOI 10.1136/gutjnl-2012-302196

In 20 coeliac adults, 3 g gluten daily for 14 days halved villus height ratio; symptoms rose and then went back to baseline by day 28.

Does the study support the specific claim? No · Methodological quality: moderate

Study explained simply

What did the researchers want to find out?: Measure how fast gluten harms coeliac patients.
How was the study done?: Gluten challenge with repeated biopsies.
How many people, animals or samples were studied?: 20 adults.
What was actually found?: Marked villous damage in 14 days.
How large was the observed effect?: Vh:Cd 2.2 to 1.1.
What do the results mean in everyday life?: Feeling fine does not mean the gut is fine.
What are the study's limitations?: Small, no placebo.
What does it say about Elawady's specific claim?: Contradicts symptom-guided gluten reintroduction.
Do the results apply to Germany and Europe?: High.
What can explicitly not be concluded from this study?: Does not measure long-term complications.

Authors: Leffler D et al.
Journal: Gut
Year: 2013
Identifier: PMID 22619366 DOI 10.1136/gutjnl-2012-302196 · PMC3525791
Verification: verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: not stated in abstract/PubMed record

How quickly do histology, serology and symptoms respond to gluten challenge in treated adult coeliac disease?

Study design: Randomised controlled trial – Randomised dose-comparison gluten challenge study (two doses)
Population: Adults with biopsy-proven coeliac disease on a gluten-free diet
Country: not stated in abstract (NIH-funded)
Period: not stated in abstract
Sample size: 20
Inclusion and exclusion criteria: Biopsy-proven coeliac disease

Exposure / intervention: 3 g or 7.5 g gluten/day for 14 days
Comparator: Baseline (run-in) and dose comparison
Endpoints: Vh:Cd, IEL count, tTG and DGP antibodies, lactulose/mannitol, symptoms
Statistical methods: Paired comparisons

Results: Vh:Cd fell from 2.2 to 1.1 (p<0.001) and IELs rose from 32.6 to 51.8 (p<0.001) by day 14. Antibodies rose slightly by day 14 and markedly by day 28. GI symptoms increased by day 3 and returned to baseline by day 28. No difference between doses.
Absolute risks: not reported
Authors' conclusion: A 14-day challenge with >=3 g gluten/day induces histological and serological changes in most adults with coeliac disease.

Mucosal damage halved Vh:Cd within two weeks while symptoms subsided by day 28: symptoms do not track damage.

Shows that "pause gluten when symptoms appear" is unsafe: damage occurs fast and symptoms can fade while damage and antibodies progress.

I-GRN-110 (a minority develop latency).

High.

Clear mechanistic-clinical evidence.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	moderate
Risk of bias	some concerns
Precision of results	low
Directness	direct
Reproducibility	partly replicated
Consistency with the overall evidence	consistent
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

None for the claim.